Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak Sampath

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Blood|November 2, 2014
Preclinical efficacy of MEK inhibition in Nras-mutant AMLMichael R Burgess, Eugene Hwang, Ari J Firestone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2010
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical modelsCarol O'Brien, Jeffrey J Wallin, Deepak Sampath, et al.
Genes & Cancer|July 24, 2014
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibitionKyle A Edgar, Lisa Crocker, Eric Cheng, et al.
The Prostate|July 17, 2015
Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactorKayvan R Keshari, David M Wilson, Mark Van Criekinge, et al.
Molecular Cancer Therapeutics|January 26, 2019
Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of ResponsivenessClaudia Iavarone, Ioannis K Zervantonakis, Laura M Selfors, et al.
Plos Genetics|June 15, 2019
Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemiasBenjamin J Huang, Anica M Wandler, Lauren K Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2017
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast CancerUzma S Asghar, Alexis R Barr, Ros Cutts, et al.
Neoplasia (New York, N.Y.)|November 9, 2013
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618Yang Xiao, Kristi Elkins, Jenni K Durieux, et al.
Nature|July 22, 2014
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemiaMonique Dail, Jason Wong, Jessica Lawrence, et al.
Science Signaling|December 5, 2013
PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic KrasErnesto Diaz-Flores, Hana Goldschmidt, Philippe Depeille, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Blood|November 2, 2014
Preclinical efficacy of MEK inhibition in Nras-mutant AMLMichael R Burgess, Eugene Hwang, Ari J Firestone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2010
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical modelsCarol O'Brien, Jeffrey J Wallin, Deepak Sampath, et al.
Genes & Cancer|July 24, 2014
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibitionKyle A Edgar, Lisa Crocker, Eric Cheng, et al.
The Prostate|July 17, 2015
Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactorKayvan R Keshari, David M Wilson, Mark Van Criekinge, et al.
Molecular Cancer Therapeutics|January 26, 2019
Combined MEK and BCL-2/X<sub>L</sub> Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of ResponsivenessClaudia Iavarone, Ioannis K Zervantonakis, Laura M Selfors, et al.
Plos Genetics|June 15, 2019
Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemiasBenjamin J Huang, Anica M Wandler, Lauren K Meyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2017
Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast CancerUzma S Asghar, Alexis R Barr, Ros Cutts, et al.
Neoplasia (New York, N.Y.)|November 9, 2013
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618Yang Xiao, Kristi Elkins, Jenni K Durieux, et al.
Nature|July 22, 2014
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemiaMonique Dail, Jason Wong, Jessica Lawrence, et al.
Science Signaling|December 5, 2013
PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic KrasErnesto Diaz-Flores, Hana Goldschmidt, Philippe Depeille, et al.
Pageof 10